Microbead arrays for the analysis of erbb receptor tyrosine kinase activation and dimerization in breast cancer cells

Assay and Drug Development Technologies

Volumn 8, Issue 1, 2010, Pages 27-36

  Khan, Imran H ^a,b   Zhao, Jing ^a   Ghosh, Paramita ^a,c   Ziman, Melanie ^a   Sweeney, Colleen ^c   Kung, Hsing Jien ^c   Luciw, Paul A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA NORTHERN CALIFORNIA HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 3; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; NEU DIFFERENTIATION FACTOR;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CELL ACTIVATION; CONTROLLED STUDY; DIMERIZATION; DRUG SCREENING; ENZYME ACTIVATION; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; KINETICS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SQUAMOUS CELL CARCINOMA; WESTERN BLOTTING;

BREAST NEOPLASMS; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; NEUREGULIN-1; PHOSPHORYLATION; PROTEIN ARRAY ANALYSIS; PROTEIN MULTIMERIZATION; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3;

EID: 77649098500     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2009.0208     Document Type: Article

References (29)

1. Stern DF: ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008;13:215-223.
2. Lo HW, Hsu SC, Hung MC: EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocalization. Breast Cancer Res Treat 2006;95:211-218.
3. Ono M, Kuwano M: Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs. Clin Cancer Res 2006;12:7242-7251.
4. Sweeney C, Miller JK, Shattuck DL, Carraway KL: ErbB receptor negative regulatory mechanisms: implications in cancer. J Mammary Gland Biol Neoplasia 2006;11:89-99.
5. Agrawal A, Gutteridge E, Gee JM, Nicholson RI, Robertson JF: Overview of tyrosine kinase inhibitors in clinical breast cancer. Endocr Relat Cancer 2005;12(Suppl 1):S135-S144.
6. Niu G, Carter WB: Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathway. Cancer Res 2007;67:1487-1493.
7. Engel RH, Kaklamani VG: HER2-Positive breast cancer: current and future treatment strategies. Drugs 2007;67:1329-1341.
8. Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, Baust H, Gingerich J, et al.: Targeting the EGFR pathway for cancer therapy. Curr Med Chem 2006;13:3483-3492.
9. Leong TY, Leong AS: Controversies in the assessment of HER-2: more questions than answers. Adv Anat Pathol 2006;13:263-269.
10. Britsch S: The neuregulin-I/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol 2007;190:1-65.
11. Stortelers C, van der Woning SP, Jacobs-Oomen S, Wingens M, van Zoelen EJ: Selective formation of ErbB-2/ErbB-3 heterodimers depends on the ErbB-3 affinity of epidermal growth factor-like ligands. J Biol Chem 2003;278:12055-12063.
12. Graus-Porta D, Beerli RR, Daly JM, Hynes NE: ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 1997;6:1647-1655.
13. Abd El-Rehim DM, Pinder SE, Paish CE, Rampaul RS, Balmey RW, Robertson JFR, et al.: Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive carcinoma. Br J Cancer 2004;91:1532-1542.
14. Normanno N, Maiello MR, De Luca A: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): Simple drugs with a complex mechanism of action? J Cell Phys 2002;194:13-19.
15. Khan IH, Mendoza S, Rhyne P, Ziman M, Tuscano J, Eisinger D, et al.: Multiplex Analysis of intracellular signaling pathways in lymphoid cells by microbead suspension arrays. Mol Cell Proteomics 2006;5:758-768.
16. Crovello CS, Lai C, Cantley LC, Carraway KL, III: Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2. J Biol Chem 1998;273:26954-26961.
17. Lupu R, Colomer R, Kannan B, Lippman ME: Characterization of a growth factor that binds exclusively to the erbB-2 receptor and induce cellular responses. Proc Natl Acad Sci USA 1992;89:2287-2291.
18. Zaczek A, Brandt B, Bielawski KP: The diverse signaling network of EGFR, Her2, HER3 and HER4 tyrosine kinase receptors and the consequences of therapeutic approaches. Histol Histopathol 2005;20:1005-1015.
19. Anido J, Matar P, Albanell J, Guzman M, Rojo F, Arribas J, et al.: ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 2003;9:1274-1283.
20. Citri A, Yarden Y: EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006;7:505-516.
21. Karamouzis MV, Badra FA, Papavassiliou AG: Breast cancer: the upgraded role of HER-3 and HER-4. Int J Biochem Cell Biol 2007;39:851-856.
22. Jimeno A, Hidalgo M: Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. Biochim Biophys Acta 2006;1766:217-229.
23. Chan SK, Hill ME, Gullick WJ: The role of the epidermal growth factor receptor in breast cancer. J Mammary Gland Biol Neoplasia 2006;11:3-11.
24. Reimer U, Reineke U, Schneider-Mergener J: Peptide arrays: from macro to micro. Curr Opin Biotechnol 2002;13:315-320.
25. Imam-Sghiouar N, Laude-Lemaire I, Labas V, Pflieger D, Le Caer JP, Caron M, et al.: Subproteomics analysis of phosphorylated proteins: application to the study of B-lymphoblasts from a patient with Scott syndrome. Proteomics 2002;2:828-838.
26. Steinberg TH, Agnew BJ, Gee KR, Leung WY, Goodman T, Schulenberg B, et al.: Global quantitative phosphoprotein analysis using Multiplexed Proteomics technology. Proteomics 2003;3:1128-1144.
27. Brill LM, Salomon AR, Ficarro SB, Mukherji M, Stettler-Gill M, Peters EC: Robust phosphoproteomic profiling of tyrosine phosphorylation sites from human T cells using immobilized metal affinity chromatography and tandem mass spectrometry. Anal Chem 2004;76:2763-2772.
28. Veenstra TD, Prieto DA, Conrads TP: Proteomic patterns for early cancer detection. Drug Discov Today 2004;9:889-897.
29. Ficarro SB, Salomon AR, Brill LM, Mason DE, Stettler-Gill M, Brock A, et al.: Automated immobilized metal affinity chromatography/nano-liquid chromatography/ electrospray ionization mass spectrometry platform for profiling protein phosphorylation sites. Rapid Commun Mass Spectrometry 2005;19: 57-71.